natgillin/translations-raw huggingface dataset:
A method according to any of claims 1-5, wherein the solution obtained in step (iv) is mixed with fat phase within 5 hours, preferably within 2 hours, packed in containers, and preferably stored at 4 to 10°C for at least 24 hours. 
Postupak prema bilo kojem od zahtjeva 1-5, gdje se otopina dobivena u koraku (iv) miješa s masnom fazom unutar 5 sati, poželjnije 2 sata, pakira u spremnike i poželjno čuva pri 4 do 10%C najmanje 24 sata.
X12, for each occurrence, is independently CH, CR9, N, N(O), N+(R17), provided that at least one X12 group is independently selected from CH and CR9; 
X, u svakom slučaju je nezavisno CH, CRo, N, N(O), N'(Ry9), pod uvjetom da barem jedna X,, skupina je nezavisno izabrana od CH i CRg;
D2O (disappears upon deuteration). 
DO (nestaje nakon deuterizacije).
An anti-N3pGlu AB antibody or antigen-binding fragment thereof for use according to claim 1 or for use according to claim 2, wherein the antibody or antigen-binding fragment thereof comprises a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein said LCVR comprises LCDR1, LCDR2, and LCDR3 polypeptides and HCVR comprises HCDR1, HCDR2, and HCDR3 polypeptides which are selected from the group consisting of: 
Protutijelo protiv N3pGlu AB, ili njegov antigenski vežući fragment, namijenjeno upotrebi u skladu s patentnim zahtjevom 1 ili namijenjeno upotrebi u skladu s patentnim zahtjevom 2, naznačeno time što protutijelo, ili njegov antigenski vežući fragment, sadrži varijabilno područje lakog lanca (LCVR) i varijabilno područje teškog lanca (HCVR), gdje navedeni LCVR sadrži polipeptide LCDR1, LCDR2, te LCDR3, a HCVR sadrži polipeptide HCDR1, HCDR2, te HCDR3, koje se bira iz skupine koju čine:
A compound of formula VIb: 
Spoj, naznačen time, da ima formulu VIb:
A method of delivering a molecule into a cell comprising contacting the cell with the complex of claim 5 or 7 or the nanoparticle of any one of claims 6-9, wherein the complex or nanoparticle comprises the molecule, and wherein the contacting of the cell with the complex or nanoparticle is carried out ex vivo or in vitro. 
Metoda isporuke molekule u stanicu, koji obuhvaća kontakt stanice s kompleksnim spojem prema patentnom zahtjevu 5 1li 7, ili nanočesticom bilo kojeg od patentnih zahtjeva 6-9, pri čemu kompleksni spoj ili nanočestica sadrži molekulu i pri čemu se dodirivanje stanice s kompleksnim spojem ili nanočesticom provodi ex vivo ili in vitro.
The method of claim 14, wherein the disease or condition is a solid tumor of the colon, rectum, prostate, lung, pancreas, liver, kidney, cervix, stomach, ovaries, breast, skin, brain, meninges, or central nervous system. 
Spoj za primjenu prema patentnom zahtjevu 14 ili primjenu prema patentnom zahtjevu 15, gdje bolest ili stanje je solidni tumor debelog crijeva, rektuma, prostate, pluća, gušterače, jetre, bubrega, cerviksa, želuca, jajnika, dojke, kože, mozga, moždanih ovojnica, ili centralnog živčanog sustava.
and R4 together with the C-atom to which they are attached form a 5- or 6-membered heterocycle comprising at least one oxygen atom or nitrogen atom optionally substituted with methyl. 
R5 i R4, zajedno s C-atomom na kojeg su vezani, tvore 5- ili 6-eročlani heterocikl, koji sadrži najmanje jedan atom kisika ili atom dušika, izborno supstituiran s metilom.
The solid oral extended release pharmaceutical dosage form of any one of claims 1 to 5, wherein the active agent is oxycodone hydrochloride and wherein the dosage form when tested in a comparative clinical study is bioequivalent to the commercial product OxyContin™. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema zahtjevu 1, naznačen time da oblik doziranja kada je ispitivan u komparativnoj kliničkoj studiji je bioekvivalentan sa komercijalnim proizvodom OxyContinTM,
Thus, the patients prejudice to change from the tablet administration (à priori considered as comfortable administration) to inhalation (à priori considered as not comfortable administration), was not confirmed by practice. 
Stoga, predrasuda pacijenata za promjenu s uzimanja tableta (a priori smatranu ugodnom primjenom) na mhaliranje (a priori smatrano neugodnom primjenom) nije se potvrdila u praksi.
The antibody according to claim 9, wherein said antibody has an IC50 less than 500 nM as measured in BMP6 Smad1 phosphorylation assay in a MC3T3-E1 cell line in the presence of sclerostin. 
Protutijelo ili njegov dio koji veže antigen prema zahtjevu 9, naznačeno time da ima vrijednost ICsy manju od 1 uM, poželjno manju od 500 nM, poželjno manju od 200 nM kako je mjereno sa BMP6 Smad1 testom fosforilacije kod MC3T3-E1 stanične linije u prisutnosti sklerostina.
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the density of the extended release matrix formulation is equal to or less than about 1.20 g/cm3 preferably equal to or less than about 1.19 g/cm3. 
Farmaceutski oblik za doziranje s produljenim otpuštanjem u krutom obliku za oralnu upotrebu prema zahtjevu 1 ili 2, naznačen time da gustoća formulacije matrice s produljenim otpuštanjem je jednaka ili manja od oko 1.20 g/cm3, poželjno jednaka ili manja od oko 1.19 g/cm3.
Machinery according to claim 5, wherein the second horizontal trolley arranged downstream of the folding assembly moves on a same level of advancement as the electro-welded metal nets and is orthogonal to the flow of advancement of the electro-welded metal nets. 
Stroj prema zahtjevima 5 ili 6, naznačen time da se druga vodoravna kolica (6) koja su postavljena nizvodno od sklopa za savijanje (3) pomiču na istoj razini napredovanja kao elektro-zavarena metalna mreža, te su pravokutna na navedeno kretanje.
A matured collagen, wherein the matured collagen comprises collagen stored at a temperature of at least about 40°C for a period of at least one week or at a temperature of about 2-8°C for about 1-3 years. 
Zreli kolagen prema patentnom zahtjevu 1, naznačen time što se je dehidrirani kolagen pohranjen na temperaturi od najmanje 40 °C kroz razdoblje od najmanje šest tjedana i uz relativnu vlažnost manju od 80%.
optionally wherein the VL and VH domains comprise the amino acid sequences as shown in SEQ ID NOs: 278 and 280, respectively. 
Bispecifično protutijelo u skladu s patentnim zahtjevom 1, pri čemu VL-VEGF i VH-VEGF domene obuhvaćaju sljedove aminokiselina prikazane redom u sljedovima identifikacijskih brojeva: 278 i 280.
Another aspect of the invention is the use of an IL-17 antagonist or an IL-23 antagonist for the preparation of a pharmaceutical composition for the treatment or prevention of an autoimmune ocular inflammatory disease (AOID) in a patient. 
. Uporaba IL-17 antagonista, naznačena time, da se koristi u izradi farmaceutskog pripravka za liječenje autoimune očne upalne bolesti (AOID) kod pacijenta.
The method according to any one of claims 21 to 30, wherein in said step A7, h), said mineral acid is hydrochloric acid. 
Postupak prema bilo kojem od zahtjeva 21 do 30, naznačen time što u navedenom koraku A7, h), navedena mineralna kiselina je klorovodična kiselina.
The composition of claim 17 or 18, wherein said cytotoxic agent is coupled chemically to said antibody as a combination product for simultaneous use. 
Pripravak iz patentnog zahtjeva 14, naznačen time da dalje sadrži jedno sredstvo kao kombinacijski produkt za istodobnu, odvojenu ili uzastopnu upotrebu, pri čemu rečeno sredstvo jest antitumorsko antitijelo.
Pellets according to claim 4, wherein the weight ratio of the sodium chloride:potassium chloride is about 20:1. 
Granule sukladno patentnom zahtjevu 4, naznačene time što je težinski odnos natrijev klorid:kalijev klorid oko
The combination of claim 1, wherein the tensioning element is selected from the group consisting of coil springs, washers, Belleville spring washers and combinations thereof. 
Kombinacija iz zahtjeva 1, pri čemu je zatezni element (148) odabran između skupine koja se sastoji od spiralnih opruga, podloški, opružnih podloški i kombinacija istih.
A compound of any of claims 1-5, or a pharmaceutically acceptable salt thereof for use in a method of preventing, stabilizing, or inhibiting the growth of fungi, or killing fungi. 
Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, za upotrebu u prevenciji, stabilizaciji ili inhibiciji rasta gljivica ili istrebljenju gljivica.
Use as claimed in any of the preceding claims, for the manufacture of a medicament for the treatment or prevention of an autoimmune inflammatory disease. 
Spoj za uporabu prema zahtjevu 1 za liječenje ili prevenciju autoimune upalne bolesti.
The compound or salt of any one of claims 1-3, wherein R3 is C1-C6 alkyl or 3-7 membered heterocycloalkyl, wherein the C1-C6 alkyl is optionally substituted by one or two R14 groups, and further wherein the 3-7 membered heterocycloalkyl is optionally substituted by C1-C3 alkyl. 
Spoj ili sol u sklađu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što je R* C,-C; alkil ili 3-7-eročlani heterocikloalkil, gdje C,-C4 alkil može biti supstituiran s jednom ili dvije skupine R *, te gdje dodatno 3-7-eročlani heterocikloalkil može biti supstituiran s Cy-C3 alkilom.
The method of claim 20, wherein the cancer is pancreatic cancer, prostate cancer, lung cancer, melanoma, breast cancer, colon cancer, or ovarian cancer. 
Spoj ili farmaceutski pripravak za primjenu sukladno zahtjevu 8,, naznačen time, da je rak rak pankreasa, rak prostate, rak pluća, melanom, rak dojke, rak debelog crijeva, ili karcinom jajnika.
The implantation alignment tool of claim 1, wherein said stabilization structure comprises an a metal, metal alloy, ceramic, glass or plastic and may optionally incorporate a flexible or shock-absorbing material. 
Pribor za kalibraciju implantata iz patentnog zahtjeva 1, pri čemu se navedena stabilizacijska struktura sastoji od metala, metalnih legura, keramike, stakla ili plastike i eventualno može sadržavati fleksibilan ili amortizirajući materijal.
The preferred embodiment, the enantiomer trans-(1R)-N-methyl-4-phenyl-l,2,3,4-tetrahydro-l-naphthalenamine and its pharmaceutically acceptable acid addition salts, exhibits excellent synaptosomal norepinephrine uptake blocking activity. 
Poželjna realizacija, enantiomer trans-(1R)-N-metil-4-fenil-1,2,3,4-tetrahidro-1-naftalinamina i njegove farmaceuiski prihvatljive aditivne soli s kiselinama, pokazuju sjajnu aktivnost za blokiranje potrošnje sinaptosomalnog norepinefrina.
A wing according to claim 2 including a support for mounting the wing on the object, on which support the wing is: (i) rotatably mountable to the object; or (ii) fixed to the object. 
Krilo sukladno zahtjevu 2 koje sadrži nosač za montažu krila na objekat, pri čemu se na nosaču krilo: (i) može okretno postavljen na objektu; ili (ii) može biti pričvršćeno na objekat.
tableting the final mixture of step (4) by compressing it on a suitable tablet press to produce matrix tablets. 
(5) tabletiranje konačne mješavine iz koraka (4) njezinim komprimiranjem u prikladnoj preši za tablete da bi so pripravile matrice tableta. t>&
LDPC-decoding the Layer 1 signaling data and the de-punctured parity bit; and 
LDPC dekodiranje signalnog podatka razine 1 i sabijenog paritetnog bita; 1
and wherein when the ratio of the percentage of cells to the percentage of cell culture conditioned medium in the sample portion deviates from 1:1, the fraction of viable cells in the tissue-engineered product can be calculated according to the formula: EPMATHMARKEREP wherein EPMATHMARKEREP and f is the fraction of the total sample conditioned medium present in portion of the cell culture conditioned medium not containing cells of the cell population; 
HR P20140825 T1 pri čemu i fje udio ukupnog uzorka kondicioniranog medija koji je prisutan u dijelu kondicioniranog medija stanične kulture koji ne sadržava stanice iz populacije stanica; i pri čemu kada je omjer postotka stanica prema postotku kondicioniranog medija stanične kulture u dijelu uzorka odstupa od 1:1, udio vijabilnih stanica u produktu preinačenog-tkiva se može izračunati prema formuli: K-cY
a heavy chain variable region comprising, from amino terminus to carboxy terminus, a first framework region, a heavy chain CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 63, a second framework region, a heavy chain CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 65, a third framework region, a heavy chain CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 67, and a fourth framework region; wherein the binding protein binds human CD37. A humanized or chimeric CD37-specific immunoglobulin binding protein, comprising: 
Proizvodni artikl koji sadrži protein koji se specifično veže na CD20 i humanizirani protein koji se specifično veže na CD37 za upotrebu u liječenju karcinoma B-stanica ili autoimune bolesti, pri čemu humanizirani protein koji se specifično veže na CD37 sadrži: humane okvirne regije lakog lanca, laki lanac CDR1 koji sadrži aminokiselinski slijed iz SEQ ID NO:61, laki lanac CDR2 koji sadrži aminokiselinski slijed iz SEQ ID NO:64 i laki lanac CDR3 koji sadrži aminokiselinski slijed iz SEQ ID NO:66, i humane okvirne regije teškog lanca, teški lanac CDR1 koji sadrži aminokiselinski slijed iz SEQ ID NO:63, teški lanac CDR2 koji sadrži aminokiselinski slijed iz SEQ ID NO:65 i teški lanac CDR3 koji sadrži aminokiselinski slijed iz SEQ ID NO: 67 ili 68.
A pharmaceutical combination of Claim 25 wherein the lipid-modulating agents are selected from a phytoestrogen compound selected from isolated soy bean protein, soy protein concentrate, soy flour, isoflavone, genistein, daidzein, glycitein or equol, or phytosterols, phytostanol and tocotrienol; a beta-lactam cholesterol absorption inhibitor; an HDL upregulator selected from an LXR agonist, a PPAR a-agonist and an FXR agonist; an LDL catabolism promoter; a sodium-proton exchange inhibitor; an LDL-receptor inducer; steroidal glycoside; an anti-oxidant selected from beta-carotene, ascorbic acid, a-tocopherol, retinol, Vitamin C antihomocysteine agent, folic acid, a folate, Vitamin B6, Vitamin B12 and Vitamin E; isoniazid; a cholesterol absorption inhibitor; an HMG-CoA synthase inhibitor; a lanosterol demethylase inhibitor; a PPAR δ agonist for treating dyslipidemia; a sterol regulating element binding protein-I selected from a sphingolipid, ceramide, neutral sphingomyelenase or fragment thereof. 
Farmaceutski sastav Zahtjeva 25, naznačen time, da su sredstva za modulaciju lipida odabrana od spoja fitoestrogena odabranog od izoliranog proteine zrna soje, koncentrata proteina soje, soj inog brašna, izoflavona, genistin, daidzein, gliciteina ili ekviola, ili fitosterola, fitostanol i tokotrienola, inhibitora apsorpcija beta laktam kolesterola, HDL "upregulatora" odabranog od LXR agonista, PP7AR a-agonist i/ili FXR agonista; promicatelja LDL katabolizma, inhibitora izmjene natrij-proton, induktora LDL-receptora, steroidal glikozida, anti oksidanta odabranog od beta karotena, askorbinska kiselina, a-tokoferol, retinol. Vitamin C, antihomocisteinsko sredstvo, folna kiselina, folat. Vitamin B6, Vitamin B12 i Vitamina E, izoniazid, inhibitor apsorpcije kolesterola, inhibitor HMG-CoA sintaze, inhibitor lanosterol demetilaze, PPAR & agonist za liječenje dislipidemije, element regulacije sterola vezajući protein-I odabran od sfingolipida, ceramida, neutralne sfingomijelinaze i njihovih fragmenata.
By means of the planing of the adhesion surfaces, on the one hand, optically pleasing respectively hardly visible glue joints result, and on the other hand, a compact and permanent connection between the respective pieces of wood. 
Izravnavanjem površina koje se lijepe s jedne strane se postiže to, da taj spoj dobiven lijepljenjem bude jedva vidljiv i optički zadovoljavajući, a s druge strane, da bude to bude kompaktan i stalan spoj između odgovarajućih komada od drva.
Another object of this invention resides in a combination product comprising a muscarinic receptor agonist and an inhibitor of thyroid hormone synthesis, or a prodrug thereof, for a grouped or separate administration to a subject, simultaneously or sequentially. The invention also relates to a pharmaceutical composition comprising a muscarinic receptor agonist and an inhibitor of thyroid hormone synthesis, or a prodrug thereof, and a pharmaceutically acceptable carrier or excipient. 
HR P20140354 T1 PATENTNI ZAHTJEVI Sastav obuhvaća agonista muskarinskih receptora odabranog iz grupe koja se sastoji od pilokarpina, cevimelina, karbakola, metakolina i betanekola, ili njihovih soli, 1 inhibitora sinteze hormona štitnjače odabranog iz grupe koja se sastoji od metimazola, karbimazola, propiltiouracila i amiodarona, ili njihovih soli, i farmaceutski prihvatljivi nosač ili ekscipijens.
In some embodiments, the perovskite may be a perovskite of formula (H2N=CH-NH2)PbI3zBr3(1-z), wherein z is greater than 0 and less than 1. z may be as further defined hereinbefore. 
X je drugi halogenidni anion koji je različit od prvog halogenidnog aniona i zje veći od 0 1 manji od 1, a poželjno je da je z od 0, 05 do 0, 95.
modulating the signal frame by an Orthogonal Frequency Division Multiplexing, OFDM, method; and transmitting the signal frame via a signal, 
moduliranje (S1705) okvira signala pomoću OFDM metode; i odašiljanje (S1707) moduliranog okvira signala.
The compound of the above (1.) or the above (2.) or the pharmaceutical composition of any one of the above (3.)-(7.) for use in the treatment of a cardiovascular disease. 
Spoj patentnog zahtjeva 1 ili patentnog zahtjeva 2 ili farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 3- 7 za primjenu u liječenju kardiovaskularne bolesti.
generating a test leakage current and acquiring a corresponding signal (90u) proportional thereto as test-value; 
(ii) generiranjem ispitne parazitne struje i dobivanjem odgovarajućeg i proporcionalnog signala (90u),
detecting the formation of the immunological complex; and correlating the presence or absence of the immunological complex with the presence or absence of amyloid protein in the specific body part or body area, 
detektiranju formiranja imunološkog kompleksa; koreliranju prisutnosti ili odsutnosti imunološkog kompleksa s prisutnošću ili odsutnošću amiloidnog proteina u uzorku; i
The bacterial stability of these food preparations is higher since, contrary to sugar, the fibre composition is selectively fermented by beneficial bacteria which can prevent the proliferation of harmful and spoilage bacteria. 
Stabilnost tih prehrambenih proizvoda prema bakterijama je veća jer se, za razliku od šećera, sastavina vlakana selektivno fermentira djelovanjem korisnih bakterija, čime se može spriječiti proliferacija štetnih bakterija i onih koje uzrokuju kvarenje.
These pharmaceutical preparations can be prepared with conventional procedures using ingredients known in technique, such as ligands, disintegrants, lubricants, fillers, stabilizing agents, diluents, dyes, flavours, wetting agents and other excipients known to those skilled in the art. 
Ti farmaceutski pripravci se mogu pripraviti konvencionalnim postupcima upotrebom sastojaka poznatih u tehnici, kao što su Ugandi, dezintegrirajuća sredstva, klizna sredstva, stabilizatori, razrjeđivači, bojila, tvari za poboljšanje okusa ili drugi ekscilijensi poznati u struci.
The biologically degradable composite material can also be characterised in that the density of the inorganic component (a) is approximately 0.8-1.5 g/cm3 and the density of the inorganic component (b) is approximately 0.5-0.9 g/cm3, with the proviso that the density of the inorganic component (b) is less than that of the inorganic component (a) and the difference in density is at least 0.1 g/cm3. 
Biološki razgradivi kompozitni materijal u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time, da je gustoća mase anorganske komponente (a) približno 0,8-1,5 g/em? i gustoća mase anorganske komponente (b) je približno 0,5-0,9 g/em*, pod uvjetom da je gustoća anorganske komponente (b) manja od one anorganske komponente (a), a razlika u gustoći iznosi najmanje 0,1 g/em*.
The solution was brought to reflux and dichloromandelic anhydride (66.6gm, 398.9 mmol) was added portionwise. 
Otopina je dovedena do refluksa i u obrocima je dodan dikloromandelinski anhidrid (66.6 mg, 398.9 mmol).
A compound of any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, for use in method of treating (a) an immune-based disease in a patient; (b) cancer; or (c) a lung disease. 
Spoj prema bilo kom od zahtjeva 1 do 13, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za upotrebu u postupku tretmana (a) auto imune bolesti pacijenata; (b) raka; ili (c) bolesti pluća.
and R5, which may be identical to or different from each other, each represent a hydrogen atom, or a C1 to C6 linear, branched, or cyclic alkyl group (the alkyl group optionally being substituted by a halogen atom, a hydroxyl group, a C1 to C6 alkoxy group, a phenyl group, a benzyloxy group, or a hydroxyphenyl group), or R4 or R5, and R6 or R7 may be linked to the adjacent nitrogen atom to form a pyrrolidine ring or a piperidine ring (the pyrrolidine ring or the piperidine ring optionally being substituted by a hydroxyl group); 
i R5, koji mogu biti identični ili međusobno različiti, svaki predstavlja atom vodika, ili linearni C1 do C6, razgranatu ili cikličku alkil skupinu (alkilna skupina je po izboru supstituirana atomom halogena, hidroksilnom skupinom, C1 do C6 alkoksi skupinom, fenilnom skupinom, benziloksi skupinom ili hidroksifenil skupinom), ili R4 ili R5 i R6 ili R7 mogu biti povezani sa susjednim atomom dušika te tvore pirolidinski prsten ili piperidinski prsten (pirolidinski prsten ili piperidinski prsten po izboru su supstituirani s hidroksilnom skupinom);
The method of claim 5, wherein the composition is in the form of a food preparation, a dietary supplement, a nutraceutical, or a beverage. 
Sastav za uporabu prema zahtjevu 6, naznačen time, da se oralno davanje primjenjuje u obliku prehrambenog proizvoda, dodatka prehrani, nutritivnog proizvoda ili napitka.
R8a is hydrogen, lower alkyl optionally substituted by substituent group C, carbocyclic group optionally substituted by substituent group C, carbocycle lower alkyl optionally substituted by substituent group C, carbocycleoxy lower alkyl optionally substituted by substituent group C, heterocyclic group optionally substituted by substituent group C, heterocycle lower alkyl optionally substituted by substituent group C, heterocycleoxy lower alkyl optionally substituted by substituent group C, —Y—S—RD1, 
R* je vodik, niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, karbociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, karbociklički niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, karbocikloksi niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, heterociklička skupina prema potrebi supstituirana sa supstituentskom skupinom C, heterociklički niži alkil prema potrebi supstituiran sa supstituentskom skupinom C, heterocikloksi niži alkil prema potrebi supstituiran sa supstituentskom skupinom C,
The coating composition according to claim 14, wherein the fatty acid derivative has a carbon chain length of not more than 22 carbon atoms. 
Sastav prema bilo kojem zahtjevu 8-11, naznačen time, da masna kiselina ili njezin derivat ima ugljikov lanac duljine od najviše 22 ugljikova atoma.
The shaft 16 is connected to a lever arrangement being comprised of four levers 19 which are mounted in a knee-joint arrangement. 
Osovina 16 je spojena na sklop poluga koji obuhvaća četiri poluge 19 koje su montirane u rasporedu s koljenastim spojem.
the target cell is infected with a human pathogen, and the immunoadhesin or antibody specifically binds an epitope of the human pathogen; or 
(a) ciljana stanica je zaražena humanim patogenom, a imunoadhezin ili antitijelo se specifično vezuje za epitop humanog patogena; ili
A modified PH20 polypeptide, comprising an amino acid replacement in an unmodified PH20 polypeptide, wherein: 
Modificirani PH20 polipeptid, koji sadrži jednu ili više aminokiselinskih zamjena u nemodificiranom PH20 polipeptidu, naznačen time što: